The global Chronic Urticaria Or Hives Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Chronic Urticaria Or Hives Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Chronic Urticaria Or Hives Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Chronic Urticaria Or Hives Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Chronic Urticaria Or Hives Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
AstraZeneca Plc
Biofrontera AG
ELORAC, Inc.
Faes Farma, SA
Genentech, Inc.
GlaxoSmithKline Plc
J Uriach Y Compania, S.A.
Mabtech Limited
Merck & Co., Inc.
Mycenax Biotech Inc.
Novartis AG
Panacea Biotec Limited

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
GDC-0853
GSK-2646264
BF-Derm-1
Bilastine
Others

Segment by Application
Clinic
Hospital
Others